References - The Burden of Chronic Obstructive Pulmonary Disease

Articles

  • Mortality trends in chronic obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression analysis. Lancet Respir Med 2014; 2: 54–62.          
  • Mackay J, Amos A. Women and Tobacco. Respirology 2003; 8: 123-130.
  • Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010 65: 14-20.
  • Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. Thorax 2014; 69: 465-473. [Societal costs of asthma, COPD and respiratory allergy].Ned Tijdschr Geneeskd 2013;157: A6562.
  • Jansson SA, Backman H, Stenling A, et al. Health economic costs of COPD in Sweden by disease severity – Has it changed during a ten years period? Respir Med 2013; 107: 1931-1938.
  • Gibson GJ, Loddenkemper R, Sibille Y, et al., eds. European Lung White Book. Sheffield, European Respiratory Society, 2013.
  • Miravittles M, Sicras A, Crespo C, et al.   Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis 2013 ; 7: 139-150.
  • Kruis AL, Smidt N, Assendelf WJJ, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 10: CD009437.
  • Boland MRS, Tsiachristas A, Kruis AL, et al. The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. BMC Pulm Med 2013; 13:40
  • Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64.

The ERS Vision film series is made possible through a foundation sponsorship by astrazeneca